Skip to main content
Clinical Trials/RPCEC00000117
RPCEC00000117
Recruiting
Phase 4

Evaluation of molecular response to treatment with Heberprot-P in patients with diabetic foot ulcers”.

Center for Genetic Engineering and Biotechnology (CIGB).0 sites156 target enrollmentMay 20, 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Diabetic foot ulcers.
Sponsor
Center for Genetic Engineering and Biotechnology (CIGB).
Enrollment
156
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 20, 2011
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Center for Genetic Engineering and Biotechnology (CIGB).

Eligibility Criteria

Inclusion Criteria

  • 1\) Have given informed consent. 2\) Patients with diabetes mellitus type 1 or 2 according to the criteria of the American Diabetes Association. 3\) Age \= 18 years. 4\) Diabetic foot ulcer deep, complicated, and no clinical signs of infection. 5\) Diabetic foot ulcer with an area \= 2 cm2\. 6\) Patients with ischemic ulcers with pressures between 0\.8 to 0\.3 index.

Exclusion Criteria

  • 1\) Signs or symptoms of local infection. 2\) Complete granulating ulcer. 3\) Pretreatment with epidermal growth factor (EGF) topically or by any means in order to study injury or other injury in the 4 weeks prior to treatment with EGF. 4\) Connective tissue diseases. 5\) Decompensated or severe systemic diseases: heart disease (acute myocardial infarction in the previous three months, unstable angina or heart failure with edema), moderate or severe hepatic insufficiency, renal insufficiency with serum creatinine \> 200 umol/L. 6\) Current or history of malignancy in the past. 7\) Psychiatric or neurological diseases that prevent the patient to give consent to participate in the study. 8\) Hemoglobin \< 100 g/L. 9\) Clinical signs of malnutrition or albumin \< 30 g/L. 10\) Hypersensitivity to the product or any of its components. 11\) Pregnancy and lactation.

Outcomes

Primary Outcomes

Not specified

Similar Trials